{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:14:37Z","timestamp":1777558477571,"version":"3.51.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s10096-023-04634-5","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T11:01:50Z","timestamp":1688986910000},"page":"1063-1072","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Synergistic combination of carvedilol, amlodipine, amitriptyline, and antibiotics as an alternative treatment approach for the susceptible and multidrug-resistant A. baumannii infections via drug repurposing"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5504-660X","authenticated-orcid":false,"given":"Erennur","family":"Ugurel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2417-4104","authenticated-orcid":false,"given":"Dilek","family":"Turgut-Balik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"4634_CR1","unstructured":"O'Neill J (2016) Tackling drug-resistant infections globally: final report and recommendations. Government of the United Kingdom.\nhttps:\/\/doi.org\/APO-63983"},{"issue":"12","key":"4634_CR2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.12998\/wjcc.v2.i12.787","volume":"2","author":"M-F Lin","year":"2014","unstructured":"Lin M-F, Lan C-Y (2014) Antimicrobial resistance in Acinetobacter baumannii: from bench to bedside. World J Clin Cases: WJCC 2(12):787","journal-title":"World J Clin Cases: WJCC"},{"key":"4634_CR3","volume-title":"Publishes list of bacteria for which new antibiotics are urgently needed.","author":"WHO","year":"2017","unstructured":"WHO (2017) Publishes list of bacteria for which new antibiotics are urgently needed. World Health Organization, Geneva"},{"key":"4634_CR4","first-page":"318","volume":"27","author":"E Tacconelli","year":"2017","unstructured":"Tacconelli E, Magrini N, Kahlmeter G, Singh N (2017) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics.\u00a0World Health Organ\u00a027:318\u2013327","journal-title":"World Health Organization"},{"key":"4634_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-0-387-77944-7","volume-title":"Importance of Acinetobacter spp. Acinetobacter Biology and Pathogenesis","author":"E Bergogne-Berezin","year":"2008","unstructured":"Bergogne-Berezin E (2008) Importance of Acinetobacter spp. Acinetobacter Biology and Pathogenesis. Springer, pp 1\u201318"},{"issue":"11","key":"4634_CR6","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1128\/jcm.35.11.2819-2825.1997","volume":"35","author":"H Seifert","year":"1997","unstructured":"Seifert H, Dijkshoorn L, Gerner-Smidt P, Pelzer N, Tjernberg I, Vaneechoutte M (1997) Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods. J Clin Microbiol 35(11):2819\u20132825","journal-title":"J Clin Microbiol"},{"issue":"3","key":"4634_CR7","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1128\/CMR.00058-07","volume":"21","author":"AY Peleg","year":"2008","unstructured":"Peleg AY, Seifert H, Paterson DL (2008) Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21(3):538\u2013582","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"4634_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4103\/0974-777X.68538","volume":"2","author":"V Manchanda","year":"2010","unstructured":"Manchanda V, Sanchaita S, Singh N (2010) Multidrug resistant acinetobacter. J Global Infect Dis 2(3):291","journal-title":"J Global Infect Dis"},{"issue":"1","key":"4634_CR9","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1080\/22221751.2019.1698273","volume":"8","author":"O Ayobami","year":"2019","unstructured":"Ayobami O, Willrich N, Harder T, Okeke IN, Eckmanns T, Markwart R (2019) The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis. Emerg Microbes Infect 8(1):1747\u20131759","journal-title":"Emerg Microbes Infect"},{"key":"4634_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fmicb.2015.00231","volume":"6","author":"S-C Kuo","year":"2015","unstructured":"Kuo S-C, Lee Y-T, Yang Lauderdale T-L, Huang W-C, Chuang M-F, Chen C-P, Su S-C, Lee K-R, Chen T-L (2015) Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii. Front Microbiol 6:231","journal-title":"Front Microbiol"},{"issue":"8","key":"4634_CR11","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1086\/529198","volume":"46","author":"GM Eliopoulos","year":"2008","unstructured":"Eliopoulos GM, Maragakis LL, Perl TM (2008) Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 46(8):1254\u20131263","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4634_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/jac\/dkm018","volume":"59","author":"S Navon-Venezia","year":"2007","unstructured":"Navon-Venezia S, Leavitt A, Carmeli Y (2007) High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 59(4):772\u2013774","journal-title":"J Antimicrob Chemother"},{"key":"4634_CR13","doi-asserted-by":"publisher","first-page":"100779","DOI":"10.1016\/j.nmni.2020.100779","volume":"38","author":"S Mortazavi","year":"2020","unstructured":"Mortazavi S, Farshadzadeh Z, Janabadi S, Musavi M, Shahi F, Moradi M, Khoshnood S (2020) Evaluating the frequency of carbapenem and aminoglycoside resistance genes among clinical isolates of Acinetobacter baumannii from Ahvaz, south-west Iran. New Microbes New Infect 38:100779","journal-title":"New Microbes New Infect"},{"issue":"1","key":"4634_CR14","doi-asserted-by":"publisher","first-page":"e00310","DOI":"10.1128\/mSphere.00310-16","volume":"2","author":"A Giammanco","year":"2017","unstructured":"Giammanco A, Cal\u00e0 C, Fasciana T, Dowzicky MJ (2017) Global assessment of the activity of tigecycline against multidrug-resistant Gram-negative pathogens between 2004 and 2014 as part of the tigecycline evaluation and surveillance trial. Msphere 2(1):e00310\u2013e00316","journal-title":"Msphere"},{"key":"4634_CR15","volume-title":"Global antimicrobial resistance and use surveillance system (GLASS) report: 2021","author":"World Health Organization","year":"2021","unstructured":"World Health Organization (2021) Global antimicrobial resistance and use surveillance system (GLASS) report: 2021. World Health Organization"},{"issue":"10015","key":"4634_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S0140-6736(15)00470-5","volume":"387","author":"C \u00c5rdal","year":"2016","unstructured":"\u00c5rdal C, Outterson K, Hoffman SJ, Ghafur A, Sharland M, Ranganathan N, Smith R, Zorzet A, Cohn J, Pittet D (2016) International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet 387(10015):296\u2013307","journal-title":"Lancet"},{"issue":"7","key":"4634_CR17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jiac.2016.03.013","volume":"22","author":"A Thatrimontrichai","year":"2016","unstructured":"Thatrimontrichai A, Techato C, Dissaneevate S, Janjindamai W, Maneenil G, Kritsaneepaiboon S, Tanaanantarak P (2016) Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: a case-case-control study. J Infect Chemother 22(7):444\u2013449","journal-title":"J Infect Chemother"},{"issue":"12","key":"4634_CR18","doi-asserted-by":"publisher","first-page":"e0189621","DOI":"10.1371\/journal.pone.0189621","volume":"12","author":"RC Founou","year":"2017","unstructured":"Founou RC, Founou LL, Essack SY (2017) Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PLoS One 12(12):e0189621","journal-title":"PLoS One"},{"issue":"1","key":"4634_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.dsx.2008.04.005","volume":"4","author":"SH Habib","year":"2010","unstructured":"Habib SH, Saha S (2010) Burden of non-communicable disease: global overview. Diabetes Metab Syndr Clin Res Rev 4(1):41\u201347","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"4","key":"4634_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1046\/j.1440-1819.1999.00580.x","volume":"53","author":"T Hosaka","year":"1999","unstructured":"Hosaka T, Aoki T, Watanabe T, Okuyama T, Kurosawa H (1999) Comorbidity of depression among physically ill patients and its effect on the length of hospital stay. Psychiatry Clin Neurosci 53(4):491\u2013495","journal-title":"Psychiatry Clin Neurosci"},{"issue":"3","key":"4634_CR21","first-page":"346","volume":"105","author":"T Aoki","year":"2003","unstructured":"Aoki T, Sato T, Hosaka T (2003) Length of stay for medically ill patients with depression. Seishin shinkeigaku zasshi= Psychiatria et neurologia Japonica 105(3):346\u2013349","journal-title":"Seishin shinkeigaku zasshi= Psychiatria et neurologia Japonica"},{"key":"4634_CR22","doi-asserted-by":"publisher","unstructured":"Opatowski M, Tuppin P, Cosker K, Touat M, De Lagasnerie G, Guillemot D, Salomon J, Brun-Buisson C, Watier L (2019) Hospitalisations with infections related to antimicrobial-resistant bacteria from the French nationwide hospital discharge database, 2016. Epidemiol Infect 147. https:\/\/doi.org\/10.1017\/S0950268819000402","DOI":"10.1017\/S0950268819000402"},{"issue":"45","key":"4634_CR23","doi-asserted-by":"publisher","first-page":"2001886","DOI":"10.2807\/1560-7917.ES.2020.25.45.2001886","volume":"25","author":"DL Monnet","year":"2020","unstructured":"Monnet DL, Harbarth S (2020) Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance? Eurosurveillance 25(45):2001886","journal-title":"Eurosurveillance"},{"issue":"4","key":"4634_CR24","doi-asserted-by":"publisher","first-page":"106324","DOI":"10.1016\/j.ijantimicag.2021.106324","volume":"57","author":"C-C Lai","year":"2021","unstructured":"Lai C-C, Chen S-Y, Ko W-C, Hsueh P-R (2021) Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents 57(4):106324","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"4634_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13756-020-00819-1","volume":"9","author":"J Li","year":"2020","unstructured":"Li J, Wang J, Yang Y, Cai P, Cao J, Cai X, Zhang Y (2020) Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control 9(1):1\u20137","journal-title":"Antimicrob Resist Infect Control"},{"issue":"8","key":"4634_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3(8):673\u2013683","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4634_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C (2019) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18(1):41\u201358","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"4634_CR28","first-page":"157","volume":"8","author":"EAM de Oliveira","year":"2018","unstructured":"de Oliveira EAM, Lang KL (2018) Drug repositioning: concept, classification, methodology, and importance in rare\/orphans and neglected diseases. J Appl Pharm Sci 8(8):157\u2013165","journal-title":"J Appl Pharm Sci"},{"issue":"3","key":"4634_CR29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1084\/jem.173.3.699","volume":"173","author":"EP Sampaio","year":"1991","unstructured":"Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173(3):699\u2013703","journal-title":"J Exp Med"},{"key":"4634_CR30","doi-asserted-by":"crossref","unstructured":"Latif K, Ullah A, Shkodina AD, Boiko DI, Rafique Z, Alghamdi BS, Alfaleh MA, Ashraf GM (2022) Drug reprofiling history and potential therapies against Parkinson\u2019s disease. Front Pharmacol 13","DOI":"10.3389\/fphar.2022.1028356"},{"key":"4634_CR31","first-page":"2","volume":"2","author":"P Agrawal","year":"2015","unstructured":"Agrawal P (2015) Advantages and challenges in drug re-profiling. Australas J Pharm 2:2\u20133","journal-title":"Australas J Pharm"},{"issue":"11","key":"4634_CR32","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s40273-021-01065-y","volume":"39","author":"M Schlander","year":"2021","unstructured":"Schlander M, Hernandez-Villafuerte K, Cheng C-Y, Mestre-Ferrandiz J, Baumann M (2021) How much does it cost to research and develop a new drug? A systematic review and assessment. PharmacoEconomics 39(11):1243\u20131269","journal-title":"PharmacoEconomics"},{"issue":"1","key":"4634_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5582\/bst.2020.01047","volume":"14","author":"J Gao","year":"2020","unstructured":"Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14(1):72\u201373","journal-title":"Biosci Trends"},{"key":"4634_CR34","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.ijbiomac.2020.09.138","volume":"163","author":"OM Ugurel","year":"2020","unstructured":"Ugurel OM, Mutlu O, Sariyer E, Kocer S, Ugurel E, Inci TG, Ata O, Turgut-Balik D (2020) Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13). Int J Biol Macromol 163:1687\u20131696","journal-title":"Int J Biol Macromol"},{"issue":"10","key":"4634_CR35","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","volume":"6","author":"Q Cai","year":"2020","unstructured":"Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 6(10):1192\u20131198","journal-title":"Engineering"},{"key":"4634_CR36","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","volume":"72","author":"TU Singh","year":"2020","unstructured":"Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK (2020) Drug repurposing approach to fight COVID-19. Pharmacol Rep 72:1479\u20131508","journal-title":"Pharmacol Rep"},{"issue":"1","key":"4634_CR37","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/molecules22010114","volume":"22","author":"AE Laudy","year":"2017","unstructured":"Laudy AE, Kuli\u0144ska E, Tyski S (2017) The impact of efflux pump inhibitors on the activity of selected non-antibiotic medicinal products against gram-negative bacteria. Molecules 22(1):114","journal-title":"Molecules"},{"issue":"11","key":"4634_CR38","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1021\/acs.jmedchem.8b01325","volume":"62","author":"M O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly M, Kirkwood NK, Kenyon EJ, Huckvale R, Cantillon DM, Waddell SJ, Ward SE, Richardson GP, Kros CJ, Derudas M (2019) Design, synthesis, and biological evaluation of a new series of carvedilol derivatives that protect sensory hair cells from aminoglycoside-induced damage by blocking the mechanoelectrical transducer channel. J Med Chem 62(11):5312\u20135329","journal-title":"J Med Chem"},{"issue":"3","key":"4634_CR39","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ijantimicag.2017.12.014","volume":"51","author":"K Zawadzka","year":"2018","unstructured":"Zawadzka K, Bernat P, Felczak A, R\u00f3\u017calska S, Lisowska K (2018) Antibacterial activity of high concentrations of carvedilol against Gram-positive and Gram-negative bacteria. Int J Antimicrob Agents 51(3):458\u2013467","journal-title":"Int J Antimicrob Agents"},{"key":"4634_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-13-1","volume":"13","author":"L Yj","year":"2013","unstructured":"Yj L, Cz P, Zw Z, Zx Z, Chen HL, Lu WB (2013) Effects of a combination of amlodipine and imipenem on 42 clinical isolates of Acinetobacter baumannii obtained from a teaching hospital in Guangzhou, China. BMC Infect Dis 13:1\u20139","journal-title":"BMC Infect Dis"},{"issue":"1","key":"4634_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2164-15-815","volume":"15","author":"K-C Chang","year":"2014","unstructured":"Chang K-C, Kuo H-Y, Tang CY, Chang C-W, Lu C-W, Liu C-C, Lin H-R, Chen K-H, Liou M-L (2014) Transcriptome profiling in imipenem-selected Acinetobacter baumannii. BMC Genomics 15(1):1\u201313","journal-title":"BMC Genomics"},{"key":"4634_CR42","volume-title":"CLSI Document M100-S24. Wayne (Pennsylvania): Clinical and Laboratory Standards Institute. 2014","author":"P Wayne","year":"2014","unstructured":"Wayne P (2014) Performance standards for antimicrobial susceptibility testing; Twenty-Fourth Informational Supplement. In: CLSI Document M100-S24. Wayne (Pennsylvania): Clinical and Laboratory Standards Institute. 2014. Clinical and Laboratory Standards Institute Washington, DC"},{"key":"4634_CR43","doi-asserted-by":"publisher","DOI":"10.1128\/9781555817435","volume-title":"Clinical microbiology procedures handbook","author":"LS Garcia","year":"2010","unstructured":"Garcia LS (2010) Clinical microbiology procedures handbook. American Society for Microbiology Press"},{"key":"4634_CR44","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1469-0691.1998.tb00061.x","volume":"4","author":"I Phillips","year":"1998","unstructured":"Phillips I, Acar J, Bergan T, Degener J, Baquero F, Forsgren A, Schito G, Wiedemann B (1998) Methods for the determination of susceptibility of bacteria to antimicrobial agents. Terminology, EUCAST Definitive Document. Clin Microbiol Infect 4:291\u2013296","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"4634_CR45","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1046\/j.1469-0691.2000.00149.x","volume":"6","author":"European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)","year":"2000","unstructured":"European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (2000) Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect 6(9):503\u2013508","journal-title":"Clin Microbiol Infect"},{"issue":"2020","key":"4634_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jgar.2019.09.013","volume":"20","author":"Y Wang","year":"2020","unstructured":"Wang Y, Li H, Xie X, Wu X, Li X, Zhao Z, Luo S, Wan Z, Liu J, Fu L (2020) In vitro and in vivo assessment of the antibacterial activity of colistin alone and in combination with other antibiotics against Acinetobacter baumannii and Escherichia coli. J Glob Antimicrob Resist 20(2020):351\u2013359","journal-title":"J Glob Antimicrob Resist"},{"key":"4634_CR47","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.coph.2019.07.006","volume":"48","author":"Y-S Cheng","year":"2019","unstructured":"Cheng Y-S, Williamson PR, Zheng W (2019) Drug repurposing of synergistic drug combinations as an alternative approach for the treatment of severe infectious diseases. Curr Opin Pharmacol 48:92","journal-title":"Curr Opin Pharmacol"},{"key":"4634_CR48","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3389\/fmicb.2019.02719","volume":"10","author":"D Shang","year":"2019","unstructured":"Shang D, Liu Y, Jiang F, Ji F, Wang H, Han X (2019) Synergistic antibacterial activity of designed Trp-containing antibacterial peptides in combination with antibiotics against multidrug-resistant Staphylococcus epidermidis. Front Microbiol 10:2719","journal-title":"Front Microbiol"},{"issue":"10","key":"4634_CR49","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1128\/AAC.01245-15","volume":"59","author":"O Soren","year":"2015","unstructured":"Soren O, Brinch KS, Patel D, Liu Y, Liu A, Coates A, Hu Y (2015) Antimicrobial peptide novicidin synergizes with rifampin, ceftriaxone, and ceftazidime against antibiotic-resistant Enterobacteriaceae in vitro. Antimicrob Agents Chemother 59(10):6233\u20136240","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"4634_CR50","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.jdent.2013.07.006","volume":"41","author":"F Li","year":"2013","unstructured":"Li F, Weir MD, Fouad AF, Xu HH (2013) Time-kill behaviour against eight bacterial species and cytotoxicity of antibacterial monomers. J Dent 41(10):881\u2013891","journal-title":"J Dent"},{"issue":"4","key":"4634_CR51","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/ja.2011.5","volume":"64","author":"F Silva","year":"2011","unstructured":"Silva F, Louren\u00e7o O, Queiroz JA, Domingues FC (2011) Bacteriostatic versus bactericidal activity of ciprofloxacin in Escherichia coli assessed by flow cytometry using a novel far-red dye. J Antibiot 64(4):321\u2013325","journal-title":"J Antibiot"},{"key":"4634_CR52","doi-asserted-by":"publisher","unstructured":"Russo A, Gavaruzzi F, Ceccarelli G, Borrazzo C, Oliva A, Alessandri F, Magnanimi E, Pugliese F, Venditti M (2022) Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit. Infection 1\u201310. https:\/\/doi.org\/10.1007\/s15010-021-01643-4","DOI":"10.1007\/s15010-021-01643-4"},{"issue":"5","key":"4634_CR53","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ajic.2022.02.022","volume":"50","author":"P Eckardt","year":"2022","unstructured":"Eckardt P, Canavan K, Guran R, George E, Miller N, Avendano DH, Kim M, Himed K, Ramirez KHG (2022) Containment of a carbapenem-resistant Acinetobacter baumannii complex outbreak in a COVID-19 intensive care unit. Am J Infect Control 50(5):477\u2013481","journal-title":"Am J Infect Control"},{"key":"4634_CR54","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3389\/fcimb.2018.00348","volume":"8","author":"R Ayerbe-Algaba","year":"2018","unstructured":"Ayerbe-Algaba R, Gil-Marqu\u00e9s ML, Jim\u00e9nez-Mej\u00edas ME, S\u00e1nchez-Encinales V, Parra-Millan R, Pach\u00f3n-Ib\u00e1\u00f1ez ME, Pach\u00f3n J, Smani Y (2018) Synergistic activity of niclosamide in combination with colistin against colistin-susceptible and colistin-resistant Acinetobacter baumannii and Klebsiella pneumoniae. Front Cell Infect Microbiol 8:348","journal-title":"Front Cell Infect Microbiol"},{"key":"4634_CR55","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s00044-020-02507-6","volume":"29","author":"VS Foletto","year":"2020","unstructured":"Foletto VS, Serafin MB, Bottega A, da Rosa TF, Machado CS, Coelho SS, H\u00f6rner R (2020) Repositioning of fluoxetine and paroxetine: study of potential antibacterial activity and its combination with ciprofloxacin. Med Chem Res 29:556\u2013563","journal-title":"Med Chem Res"},{"key":"4634_CR56","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3389\/fmicb.2015.00750","volume":"6","author":"S Thangamani","year":"2015","unstructured":"Thangamani S, Younis W, Seleem MN (2015) Repurposing celecoxib as a topical antimicrobial agent. Front Microbiol 6:750","journal-title":"Front Microbiol"},{"issue":"1","key":"4634_CR57","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.510300124","volume":"30","author":"R Ba\u00f1ares","year":"1999","unstructured":"Ba\u00f1ares R, Moitinho E, Piqueras B, Casado M, Garc\u00eda-Pag\u00e1n JC, de Diego A, Bosch J (1999) Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 30(1):79\u201383","journal-title":"Hepatology"},{"issue":"6","key":"4634_CR58","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/rheumatology\/32.6.524-a","volume":"32","author":"L La Civita","year":"1993","unstructured":"La Civita L, Pitaro N, Rossi M, Gambini I, Giuggioli D, Cini G, Ferri C (1993) Amlodipine in the treatment of Raynaud's phenomenon. Rheumatology 32(6):524\u2013525","journal-title":"Rheumatology"},{"issue":"3","key":"4634_CR59","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/lam.13259","volume":"70","author":"Y Wang","year":"2020","unstructured":"Wang Y, Li X, Wang D, Sun S, Lu C (2020) In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii. Lett Appl Microbiol 70(3):189\u2013195","journal-title":"Lett Appl Microbiol"},{"key":"4634_CR60","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1097\/01.hjh.0000572224.73513.a7","volume":"37","author":"M Bubnova","year":"2019","unstructured":"Bubnova M, Aronov D, Vygodin V (2019) Effects of the combinations of amlodipine with an lisinopril or a carvedilol in patients with arterial hypertension and obesity. J Hypertens 37:e173\u2013e174","journal-title":"J Hypertens"},{"key":"4634_CR61","unstructured":"Thour A, Marwaha R (2019) Amitriptyline. In StatPearls. StatPearls Publishing.PMID: 30725910"},{"issue":"1","key":"4634_CR62","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ijantimicag.2018.09.003","volume":"53","author":"RG Otto","year":"2019","unstructured":"Otto RG, van Gorp E, Kloezen W, Meletiadis J, van den Berg S, Mouton JW (2019) An alternative strategy for combination therapy: interactions between polymyxin B and non-antibiotics. Int J Antimicrob Agents 53(1):34\u201339","journal-title":"Int J Antimicrob Agents"},{"key":"4634_CR63","volume-title":"Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities","author":"WHO","year":"2017","unstructured":"WHO (2017) Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. WHO, Geneva, Switzerland"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04634-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-023-04634-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04634-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T10:09:15Z","timestamp":1692094155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-023-04634-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["4634"],"URL":"https:\/\/doi.org\/10.1007\/s10096-023-04634-5","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"assertion":[{"value":"27 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}